Collaboration brings together complementary expertise and proprietary technologies to advance a next-generation radiopharmaceutical candidate with the potential to enhance tumor targeting. BOSTON, MA, September 9, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for […] The post Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program first appeared on Ratio Therapeutics .